Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
58
-
Total 13F shares, excl. options
-
11M
-
Shares change
-
+2.51M
-
Total reported value, excl. options
-
$251M
-
Value change
-
+$54.3M
-
Number of buys
-
44
-
Number of sells
-
-11
-
Price
-
$22.87
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q2 2019
61 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q2 2019.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11M shares
of 45.1M outstanding shares and own 24.32% of the company stock.
Largest 10 shareholders include Sofinnova Investments, Inc. (2.1M shares), FMR LLC (1.63M shares), BlackRock Inc. (1.15M shares), Cormorant Asset Management, LP (1M shares), PRICE T ROWE ASSOCIATES INC /MD/ (748K shares), ALLIANCEBERNSTEIN L.P. (744K shares), VANGUARD GROUP INC (490K shares), MILLENNIUM MANAGEMENT LLC (402K shares), Artal Group S.A. (400K shares), and STATE STREET CORP (322K shares).
This table shows the top 58 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.